Related Experiment Video

Updated: Nov 27, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.8K

The stimulative function of long noncoding RNA CDKN2B-AS1 in osteosarcoma by targeting the microRNA-122/CCNG1 axis

Abulaiti Abula1, Guliayixiamu Saimaiti2, Xayimardan Maimaiti1

  • 1Department of Microrepair and Reconstruction, the First Affiliated Hospital of Xinjiang Medical University, Xinjiang, P.R China.

Journal of Receptor and Signal Transduction Research
|December 7, 2020
PubMed

Insights

CDKN2B-AS1 is elevated in osteosarcoma (OS) and drives cancer progression by inhibiting miR-122-5p, which restores cyclin G1 expression. Silencing CDKN2B-AS1 hinders OS cell proliferation and invasion.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Osteosarcoma (OS) is an aggressive bone cancer with limited therapeutic options.
  • Identifying novel molecular targets and biomarkers is crucial for OS treatment.
  • The role of CDKN2B-AS1 in OS pathogenesis requires further elucidation.

Purpose of the Study:

  • To investigate the role and molecular mechanism of CDKN2B-AS1 in osteosarcoma.
  • To determine the impact of CDKN2B-AS1 modulation on OS cell behavior.
  • To explore the regulatory relationship between CDKN2B-AS1, miR-122-5p, and CCNG1.

Main Methods:

  • Quantitative real-time PCR (RT-qPCR) to assess gene expression.
  • Cell Counting Kit-8 (CCK8), EdU staining, and Transwell assays for proliferation and invasion.
  • Luciferase reporter assay to validate molecular interactions.

Main Results:

  • CDKN2B-AS1 expression was significantly upregulated in OS tissues and cells.
  • Silencing CDKN2B-AS1 using shRNAs inhibited MG63 cell proliferation and invasion.
  • CDKN2B-AS1 was found to repress miR-122-5p, leading to the restoration of CCNG1 expression.

Conclusions:

  • CDKN2B-AS1 plays a critical role in promoting osteosarcoma progression.
  • The molecular mechanism involves the repression of miR-122-5p and subsequent upregulation of CCNG1.
  • CDKN2B-AS1 represents a potential therapeutic target for osteosarcoma.
Keywords:
CCNG1Osteosarcomainvasionlong non-coding RNA CDKN2B-AS1microRNA-122proliferation

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.7K
Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells05:27

Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells

Published on: June 16, 2023

2.0K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.3K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.0K